News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Avita Medical to Present at SoCalBio Investor Conference & Exhibition


11/5/2012 9:32:48 AM

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - November 05, 2012) -

Regenerative medicine company Avita Medical Ltd. (ASX: AVH) (OTCQX: AVMXY) today announced that it will be presenting at the upcoming SoCalBio Investor Conference & Exhibition. The event will take place on November 7, 2012 at the Omni Hotel in Los Angeles, California.

The Company will be presenting in the Wound Healing & Regenerative Medicine Group.

"We are pleased to be presenting at this quality bioscience industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell® Spray-On Skin™ is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among the US investment community as we approach FDA submission."

This is a one-day conference organized annually by the Southern California Biomedical Council (SoCalBio) to showcase the strength and future of the bioscience industry in Los Angeles/Orange County and neighboring communities. For more information on the conference: http://www.socalbio.org/SocalBio_2012/home_2012.htm

ABOUT AVITA MEDICAL LTD.
Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell® Spray-On Skin™, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.


Contact:
Avita Medical Ltd.
Stella Sung, Ph.D.
Business Development Officer
Phone:+1 838-352-9400
Email: ssung@avitamedical.com

Investor Relations:
ProActive Capital Resources Group, LLC
Jeff Ramson
CEO
641 Lexington Avenue, 6th Floor
New York, NY. 10022
Phone:+1 646-863-6893
Email: jramson@proactivecapitalgroup.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES